Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Arava, Avandia's Divergent Paths: FDA Strengthens Arava Label Warning

This article was originally published in The Pink Sheet Daily

Executive Summary

As FDA advisory committee debated the fate of Avandia, the agency bolsters liver warning on Arava, another drug David Graham suggested be removed from the market.

You may also be interested in...



FDA Looked To Arava’s Safety Experience In Gauging Aubagio’s Risks

Agency’s assessment of teriflunomide for multiple sclerosis incorporated the known safety data for leflunomide, a chemically related drug with an extensive post-marketing record in rheumatoid arthritis. Despite hepatotoxicity and other safety concerns with the older drug, its clinical experience provided reassurance that Aubagio’s risks could be managed without a REMS.

Avandia's TIDE May Come In Smaller

Two advisory panels recommended that FDA allow the trial of GlaxoSmithKline's Avandia (rosiglitazone) to continue but questioned its design, providing important hints for drug companies planning post-marketing safety trials in the future.

Grassley And Baucus Turn Up Heat On GSK With Attack On Avandia Data Handling

Company's internal e-mails suggest GSK hid vital studies related to safety of Avandia relative to competitor, senators charge.

Related Content

Topics

UsernamePublicRestriction

Register

PS070906

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel